Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
Portfolio Pulse from Vandana Singh
Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) announced positive results from its Phase 3 RECOVER trial evaluating brilaroxazine, a drug for adults with schizophrenia. The trial met its primary endpoint, showing a significant reduction in symptom severity. The company expects to report further data from the ongoing trial in Q4 2024 and initiate a new trial in Q1 2024. The data will potentially support a planned NDA submission to the FDA in 2025. RVPH shares are up 5.33% following the announcement.
October 30, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals' positive trial results for its schizophrenia drug could potentially boost its stock in the short term. The company's shares are already up 5.33% following the announcement.
The positive results from the Phase 3 trial of Reviva Pharmaceuticals' schizophrenia drug have already resulted in a 5.33% increase in the company's stock. Further positive results from ongoing and future trials could continue to boost the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100